Form 4: Neurocrine Biosciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed transactions involving the company's stock on March 13, 2024.
• Delaet exercised non-qualified stock options to acquire 3,000 shares of common stock at a price of $106.02 per share.
• Simultaneously, Delaet sold 3,000 shares of common stock at a weighted average price of $140.1398 per share, with individual sales ranging from $140.00 to $140.20.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 7,507 shares of common stock and 4,367 non-qualified stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine stock transactions under a pre-arranged plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often governed by pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. These transactions can provide insights into management's perspective on the company's value, although they are often driven by personal financial planning needs.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as a significant component.
• The vesting schedule of the options (25% after one year, then monthly installments) is a fairly standard practice.
• The use of a 10b5-1 trading plan is a common and accepted method for executives to manage their stock holdings while mitigating insider trading concerns, similar to practices seen at companies like Amgen, Gilead, and Biogen.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on shareholders, as they are part of a pre-arranged trading plan and represent a small portion of the company's outstanding shares.

Key Dates